Navigation Links
Vanda Pharmaceuticals Initiates Phase III Clinical Study Aimed at Resetting the Body Clock
Date:8/26/2010

ucts under its license and sublicense agreements and other factors that are described in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Vanda's annual report on Form 10-K for the fiscal year ended December 31, 2009 and quarterly reports on Form 10-Q for the fiscal quarters ended March 31, 2010 and June 30, 2010, which are on file with the SEC and available on the SEC's website at www.sec.gov.  In addition to the risks described above and in Vanda's annual report on Form 10-K and quarterly reports on Form 10-Q, other unknown or unpredictable factors also could affect Vanda's results.  There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda.  Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein.  Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf.  The information in this release is provided only as of the date of this release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
2. Vanda Pharmaceuticals Reports Third Quarter 2007 Results
3. Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application
4. Vanda Presents Phase III Iloperidone Efficacy Data
5. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
6. Vanda Pharmaceuticals Provides Update on Iloperidone
7. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
8. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
9. Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
10. Vanda Pharmaceuticals Announces Expiration of Hart-Scott -Rodino Waiting Period for Exclusive License of Fanapt(TM)
11. Vanda Pharmaceuticals Announces U.S. Patent Allowance for a Long-Acting Injectable Formulation of Fanapt(TM) (iloperidone) in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Aug. 28, 2014 Levi & Korsinsky announces ... the United States District Court for the District of ... who purchased Galectin Therapeutics Inc. ("Galectin" or the "Company") ... 28, 2014. For more information, click here: ... during the Class Period the Company violated federal securities ...
(Date:8/28/2014)... 28, 2014 Nonin Medical, Inc., the inventor ... medical monitoring, today announced that the Food and Drug ... finger pulse oximeter for use in the ... into a telemedicine hub or kiosk through a USB ... pediatric to adult patients. The Model 3231 received EU ...
(Date:8/28/2014)... Oregon , August 28, 2014 ... Research titled, "DNA diagnostics Market (products, applications, techniques, ... Trends, Opportunities, Growth and Forecast, 2013 - 2020," ... reach $19 billion by 2020 registering a CAGR ... to provide accurate diagnosis and cost effectiveness over ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT 2Nonin Medical Announces FDA Clearance of Nonin Model 3231 USB Pulse Oximeter 2DNA Diagnostics Market is Expected to Reach $19 Billion by 2020 - Allied Market Research 2DNA Diagnostics Market is Expected to Reach $19 Billion by 2020 - Allied Market Research 3
... 2011 Quest Diagnostics Incorporated (NYSE: DGX ... and services, today announced the CE mark and European ... test on the 3M™ Integrated Cycler.  The new test, ... technique to eliminate nucleic-acid sample extraction, a time-consuming process ...
... N.J., Nov. 1, 2011 MedAvante, Inc., the world,s ... of treatments for central nervous system (CNS) disorders, announced ... 2011 Fifty Fastest Growing Companies. NJBIZ, New ... 50 Fastest Growing Companies in celebration of New Jersey,s ...
Cached Medicine Technology:Quest Diagnostics Announces Launch of Simplexa™ Direct Test for Influenza and Respiratory Viruses in Europe 2Quest Diagnostics Announces Launch of Simplexa™ Direct Test for Influenza and Respiratory Viruses in Europe 3MedAvante Is One of NJ's Fastest Growing Companies 2
(Date:8/28/2014)... Skmen.com, one of the most popular suppliers of men’s ... long sleeve sweater dresses and launched a ... unveiled sweater outfits are available at discounted rates, up ... of fact, Skmen.com’s fashionable and quality items have greatly ... company’s experienced tailors are striving to make more incomparable ...
(Date:8/28/2014)... Recently, iFitDress.com, the distinguished wedding dress manufacturer and ... bridesmaid dresses . Included in the new range are ... them are provided at deeply discounted prices, from 22 ... fast and reliable delivery service. All clients from around ... short time. As is commonly noted, international customers have ...
(Date:8/28/2014)... FL (PRWEB) August 28, 2014 ... Recovery Month throughout September. This month will be ... treatment and mental health services. Along with other ... Group is helping to spread the word about ... in 1989, honoring the work of treatment and ...
(Date:8/28/2014)... Arguments between parents may damage their relationships with their ... than 200 families were asked to make daily diary ... day, mothers and fathers rated the quality of their ... days when parents reported conflict and tension in their ... according to the study recently published in the ...
(Date:8/28/2014)... Arbor, MI (PRWEB) August 28, 2014 ... the nation’s leading intraoperative neurophysiology monitoring ("IONM") company, today ... to the position of Chief Executive Officer effective immediately. ... promoted to President and CFO in 2013 and has ... success. , “Bill’s efforts and achievements since joining ...
Breaking Medicine News(10 mins):Health News:Skmen.com: Bestselling Long Sleeve Sweater Dresses Are Offered Online Now 2Health News:New Selection of Chic Bridesmaid Dresses Available at iFitDress.com 2Health News:Millennium Treatment Group Celebrates National Recovery Month 2Health News:Parents' Fights May Strain Bonds With Their Kids 2Health News:Biotronic NeuroNetwork Announces the Promotion of Bill Gecsey to CEO 2
... significantly expand its services, treating up to 24 patients ... ... April 17 Aurora St. Luke,s Medical Center,s,new hyperbaric chamber will ... improve its regional wound care,services., (Photo: http://www.newscom.com/cgi-bin/prnh/20080417/AQTH107 ), ...
... Family Research Council,Action applauds GOP Presidential candidate Senator ... University supporting the pro-life,platform of the Republican Party. ... possible running mates., FRC Action,s Senior Vice ... Senator McCain depict his support for life as ...
... WALTHAM, Mass., April 17 Inverness Medical,Innovations, Inc. ... rapid point-of-care,diagnostic products, today announced that it will ... 24, 2008. The Company will also host a,conference ... that date to,discuss these results and other corporate ...
... improving indoor air quality, COLUMBUS, Ohio, April 17 ... Heating and Cooling is encouraging,Central Ohioans to take steps ... free of harmful pollutants., National Indoor Comfort Week(R), ... relies, and honors the men and,women who keep those ...
... 19 million Americans living with chronic kidney disease (CKD) ... Recent studies have shown that a main source of ... blood phosphate. , Now researchers at Washington University ... high blood phosphate directly stimulates calcification of blood vessels ...
... 17 RESMED INC. (NYSE: RMD ),announced today that ... the third quarter of fiscal year 2008, ended March 31, ... Pacific Time and will,host a conference call to review its ... is scheduled to begin at 1:30 p.m. Pacific Time and,will ...
Cached Medicine News:Health News:Aurora St. Luke's Medical Center Installs the Country's Second-Largest Hyperbaric Chamber 2Health News:Aurora St. Luke's Medical Center Installs the Country's Second-Largest Hyperbaric Chamber 3Health News:Aurora St. Luke's Medical Center Installs the Country's Second-Largest Hyperbaric Chamber 4Health News:Aurora St. Luke's Medical Center Installs the Country's Second-Largest Hyperbaric Chamber 5Health News:Aurora St. Luke's Medical Center Installs the Country's Second-Largest Hyperbaric Chamber 6Health News:FRC Action Praises John McCain's Pro-Life Comments 2Health News:Inverness Medical Innovations Schedules Conference Call for 10:00 a.m. ET April 24, 2008 to Discuss First Quarter 2008 Results 2Health News:National Indoor Comfort Week - A Breath of Fresh Air for Allergy Sufferers 2Health News:Readily available treatment could help prevent heart disease in kidney patients 2Health News:Readily available treatment could help prevent heart disease in kidney patients 3Health News:ResMed to Webcast Third Quarter 2008 Earnings Conference Call 2
Intermittent catheter...
Intermittent catheter...
Intermittent catheter...
Diagnostic and laboratory test reference. Get help with test preparation, interpretation, follow-up, and reimbursement....
Medicine Products: